Zydus Lifesciences Limited · NSE:ZYDUSLIFE
Zydus Lifesciences — Cadila Healthcare — Investor Presentation (November 2009)
22 slides from Zydus Lifesciences's investor presentation, November 2009
Slide 1: Cadila Healthcare Ltd Investor Presentation
Cadila Healthcare Ltd Ltd. Investor Presentation November 2009 1
Slide 2: Our Vision
Our Vision Zydus shall be a leading global healthcare provider with a robust product pipeline and sales of over $1 bn by 2010; we shall achieve sales of over $3 bn by 2015 and be a research-based pharmaceutical company by 2020… 2
Slide 3: A Snapshot
A Snapshot p One of the oldest and the 5th largest in the Indian formulations market worth over Rs. 370 bn (Source : ORG IMS MAT Sep Sep-09) 09) Operations in US, Europe, Japan, Latin America, Asia Pacific, Africa, Middle East and CIS regions g International sales in generic markets contribute
Slide 4: Priorities achieved: 2008-09
Priorities achieved : 2008-09 Strategic forays in key 9 Acquired Laboratorios Combix to enter Spain and acquired majority stake in Simayla markets Pharmaceuticals, South Africa Continued research focus 9 Invested over 6% of revenue on research. Filed IND ZYT1 with DCGI and USFDA Strengthening the 9
Slide 5: Financial highlights
Financial highlights # Net Profit and EPS excludes Exceptional Items 5
Slide 6: State of the art facilities and infrastructure
State of the art facilities and infrastructure Finished Dosage Form, Finished Dosage Form, Finished Dosage Form, Goa Sikkim Baddi API, Dabhasa Finished Dosage Form, API, Ankleshwar (USFDA approved) Moraiya (USFDA Approved) (USFDA Approved) Pantoprazole Intermediates Cytotoxic Injectables Fine Chemic
Slide 7: Core business areas and Revenue break-up (FY 08-09)
Core business areas and Revenue break-up (FY 08-09) Revenue break-up by segment Revenue break-up break up by region 7
Slide 8: 5th largest in Indian Pharma market
5th largest in Indian Pharma market with ~ Rs 14 bn sales Leading positions in key segments – CVS, GI, Female Healthcare and Respiratory Therapeutic Area-wise Sales Break-up of (participated market segments) Branded Formulations (FY 08-09) 15 brands feature amongst the top 300 brands Dermatology
Slide 9: International formulations: two-fold focus
International formulations : two-fold focus Focusing on developed generic Driving growth in emerging markets markets which constitute 22 % of which contribute to 11 % of global sales g global sales g 9 US - Zydus Pharmaceuticals USA Inc. 9 Brazil – 9 Europe • Branded - Quimica e Pharmaceutica Nikkho
Slide 10: One of the fastest growing generic companies in US
One of the fastest growing generic companies in US Gross Sales Started operations in 2005 and adopted a “Customer Centric Model” 27 products launched. 8 -10 products to be added every year Products enjoy 5 - 25% market share Focusing on delivery based, difficult to make products, the next gr
Slide 11: Over 2.5% market share in French market; launches in Spain
Over 2.5 % market share in participated French market; 24 p product launches in Spain p Strong presence in Euro 2.3 bn French market Gross Sales Rated one of the fastest growing companies in France by IMS Launched >150 presentations (~75 molecules) in France Continuous focus on enrichment of c
Slide 12: Strategies for world's 2nd largest market: Japan
Strategies for world’s 2nd largest market valued at $3bn : Japan p Market valued at $ 3 bn, growing at ~12%, with very low generic penetration of ~5% in value terms, 17% in volume terms (Source : IGPA) Acquired Nippon Universal Pharma. Ltd. (NUP) with a marketing set-up and a small manufacturing
Slide 13: Achievements in the $12bn Brazilian pharma market
Achievements in the $ 12bn Brazilian pharma market growing at 15 15-18% 18% p.a. Gross Sales Set up Zydus Healthcare Brazil Ltda (100% subsidiary) to enter generics market in 2005-06 2005 06 Filed 49 dossiers so far for generic and branded products from India, of which 19 have been approved Laun
Slide 14: Exports to emerging markets grew by >30%
Exports to emerging markets grew by >30% in last 4 years y Gross Sales Operations in over 20 semi / non regulated emerging markets of Asia Pacific, Africa, Middle East and CIS regions Focusing on rapidly growing markets of Russia, South Africa, Taiwan and Philippines No.1 Indian company in Uga
Slide 15: Zydus Wellness – A market leader with iconic and niche consumer brands
Zydus Wellness – A market leader with iconic and niche consumer brands Restructured consumer business with de-merger of consumer business from Cadila Healthcare into Carnation in FY 08-09. Company now renamed as Zydus Wellness Ltd. 15
Slide 16: Pioneer in low calorie sweetener and skincare products
A pioneer in the low calorie sweetener segment and a trendsetter in skincare products Sugar Free – India’s largest selling sugar substitute with market share of over 82% (Source : AC Nielsen). Growing at CAGR of 25% for last 3 years, th the b brand d recorded d d sales l of Rs. 778 Mio. in FY 08
Slide 17: Unlocking value through win-win alliances
Unlocking value through win-win alliances Zydus Nycomed JV – most successful contract manufacturing JV in India State-of-the-art API mfg. plant for Pantoprazole intermediates Expanded scope - more APIs to be sourced by Nycomed from this JV Z d Hospira Zydus H i - JV ffor oncology l injectabl
Slide 18: Ongoing Investment in Newer Portfolios
Ongoing Investment in Newer Portfolios Worth over $ 180 bn Zydus New Portfolio Mid term Zydus New Portfolio • Biogenerics Biogenerics: 40 bn Near term • Transdermal: 10 bn • Vaccine: 22 bn Oral • Pulmonary: 20 bn • Topical: 16 bn • Transdermal: 10 bn • One of the leading player • Injectables: 17 bn
Slide 19: A scientific talent pool of 850 and investing over 6% on research
A scientific talent pool of 850 and investing over 6% of the turnover on research Talent Pool of ~850 Scientists Zydus Research Centre (ZRC) Located L t d iin Ah Ahmedabad d b d Generics/ Developmental Focus on NME Research, 335 scientists Biologicals & NDDS Pharmaceutical Technology Centre NME
Slide 20: Dedicated facility for NME research: Zydus Research Centre
Dedicated facility for NME research : Zydus Research Centre Areas of focus: Dyslipidemia, Diabetes, Obesity, Inflammation Facility for target identification to pre-clinical research / early clinical development 2nd company in India to be accredited by AAALAC (Association for Assessment and Acc
Slide 21: Highlights: H1 FY 09-10 Results
Highlights : H1 FY 09-10 Results Rs. Mio. Consolidated Growth H1 09-10 H1 08-09 y-y% Domestic Sales 9,770 8,717 12.1% Exports Sales 8 376 8,376 5 847 5,847 43 3% 43.3% Total Gross Sales 18,146 14,564 24.6% Total Operating Income 18,493 14,550 27.1% EBIDT 4,093 3,142 30.3% EBIDT % to Total Income 22.
Slide 22: Safe Harbour Statement
Safe Harbour Statement This presentation may include certain “forward looking statements” , based on current expectations, within the meaning of applicable laws and regulations. Actual results may differ and the company does not guarantee realization of these statements. state e ts The e Company Co
Cadila Healthcare — Investor Presentation (November 2009) on 6ix